Program: Oral and Poster Abstracts
Session: 651. Myeloma: Biology and Pathophysiology, excluding Therapy: Poster II
Methods: Exploratory objectives included evaluation of chromosomal abnormalities, BCL-2 family member gene expression levels, and ex vivo sensitivity of pt MM tumor cells to VEN and/or BTZ. Interphase FISH analysis was performed on CD138-positively selected bone marrow mononuclear cells (BMMC) using probes for t(11;14), t(4;14), deletion 17p (17p–), deletion 13q (13q–), and amplification of chromosomes 5, 9, or 15 (denoted as hyperdiploid [HY]). Absolute quantitation of BCL-2 family members (BCL-2, BCL-XL, MCL-1, BCL-2A1, BIM, BID, BAD, BAX, and NOXA) was performed on CD138-selected BMMCs collected at baseline using TaqMan probe-based droplet digital polymerase chain reaction. Ex vivo sensitivity of BMMCs collected at baseline to increasing doses of VEN and/or BTZ was determined by flow cytometry using a combined analysis for the loss of CD138 surface expression and the alteration of cellular morphology (lower FCS). Correlations between biomarkers and median best percentage change in M-protein were examined by Spearman test. Correlations between biomarkers and median time on study (mToS) were examined by log-rank and Wilcoxon tests for binary biomarkers, and by risk ratio from a Cox proportional hazard model for continuous biomarkers. No correction for multiple testing was performed.
Results: Forty-one pts were enrolled as of 06/15/2015. The biomarker study subgroups were similar to the overall pt population with respect to demographics. Of the 37/41 (90%) pts assessed by FISH, 5 were t(11;14), 3 were t(4;14), 20 were 13q–, 10 were 17p–, and 15 were HY. In pts with HY, median best percentage change in M-protein was –79.4% compared to +101.65% in non-HY, while mToS was 309 days compared to 29 days in non-HY (p <0.0001), consistent with literature regarding a positive prognostic effect in MM. No difference in efficacy was observed in other FISH subtypes. BCL-2 family gene expression levels were determined in 25/41 (61%) pts. BCL-2, but not BCL-XL or MCL-1 gene expression, correlated with M-protein response (Spearman –0.5116, p=0.0149) and with a trend for increased mToS (HR=0.42 [95% CI 0.13–1.0]). Responders (≥ partial response, n=13; assessed by International Myeloma Working Group criteria 2011) had higher BCL-2 levels than subjects with stable disease/progressive disease (n=12; p=0.015). Pts with high BCL-XL or high MCL-1 were found in both the responder and nonresponder populations. Of the 14 pt samples collected for ex vivo sensitivity, 8 had sufficient CD138-positive cells for VEN ± BTZ dose curve analysis. Four of 8 (50%) were sensitive to VEN alone (median lethal dose [LD50] ≤300 nM) while 4/8 (50%) were sensitive to BTZ alone (LD50 ≤5 nM). Seven of 8 (88%) were sensitive to the combination (LD50 ≤5 nM BTZ/300 nM VEN).
Conclusions: VEN in combination with BTZ and dexamethasone is active in R/R MM. CD138-enriched BMMCs were obtained in sufficient numbers to enable downstream FISH analysis, BCL-2 family gene expression profiling, and ex vivo sensitivity evaluation. The exploratory biomarker analysis showed that higher BCL-2 gene expression levels at baseline significantly correlated with clinical responses to therapy, with a trend toward increased mToS. Additionally, MM cells treated ex vivo demonstrated greater sensitivity to the combination of VEN/BTZ than to the 2 single agents alone. Further investigation of this dataset continues, including analysis of on-treatment tumor samples in a subset of pts.
Disclosures: Ross: AbbVie: Employment , Equity Ownership . Off Label Use: Venetoclax is an investigational drug that is not yet approved in this indication.. Chyla: AbbVie: Employment , Equity Ownership . Roberts-Rapp: AbbVie: Employment , Equity Ownership . Goswami: AbbVie: Employment , Equity Ownership . Yan: AbbVie: Employment , Equity Ownership . Huang: AbbVie: Employment , Equity Ownership . Bhathena: AbbVie: Employment , Equity Ownership . Enschede: AbbVie: Employment , Equity Ownership . Maciag: AbbVie: Employment , Equity Ownership . Humerickhouse: AbbVie: Employment , Equity Ownership . McKeegan: AbbVie: Employment , Equity Ownership .
See more of: Myeloma: Biology and Pathophysiology, excluding Therapy
See more of: Oral and Poster Abstracts
*signifies non-member of ASH